Momentis Surgical announced the FDA granted 510(k) clearance for its second-generation Anovo surgical robot. Last month, Anovo received clearance for use in single-site, abdominal access across ventral hernia repair. It complemented Anovo’s existing approvals for natural orifice laparoscopic-assisted transvaginal benign gynecology procedures. Momentis said the system became the first and only FDA-authorized surgical robot platform that features miniature humanoid-shaped robotic arms that provide human-level dexterity, multi-planar flexibility and 360 degrees of articulation.
Related: Limaca’s Precision-GI™ granted CMS Transitional Pass-Through payment
The second-generation Anovo platform brings a suite of upgrades to enhance surgeon experience and ease of use. That includes the first FDA-cleared robotic system capable of operating in both retroflextion and anteflexion, according to a news release.
Surgeons can also now experience enhanced ergonomics with integrated haptic feedback, creating more intuitive control of the robotic arms. The system also has a new annotation-enabled video overlay, enhancing in-room communication and supporting teaching and collaboration.
“This second-generation platform, combined with our expanded surgical indications, underscores our commitment to the long-term plan of transforming the field of robotic surgery with our versatile surgical platform,” said Dvir Cohen, CEO of Momentis Surgical. “This new FDA clearance is another milestone in the execution of our long term plan to take robot-assisted surgeries to the next level. We are building strong momentum following the impressive clinical outcomes we’ve achieved in gynecology.
“Our focus now is on expanding Anovo’s applications to additional indications, including general surgery. Alongside these advancements, we aim to broaden our global presence and look forward to introducing Anovo to markets in Europe and Asia in the future.”
